TW202329916A - 包含生物醫藥藥物化合物之新穎醫藥組合物 - Google Patents

包含生物醫藥藥物化合物之新穎醫藥組合物 Download PDF

Info

Publication number
TW202329916A
TW202329916A TW111145223A TW111145223A TW202329916A TW 202329916 A TW202329916 A TW 202329916A TW 111145223 A TW111145223 A TW 111145223A TW 111145223 A TW111145223 A TW 111145223A TW 202329916 A TW202329916 A TW 202329916A
Authority
TW
Taiwan
Prior art keywords
composition
compositions
vaccine
biopharmaceutical
composition according
Prior art date
Application number
TW111145223A
Other languages
English (en)
Chinese (zh)
Inventor
約納斯 塞夫馬克
羅伯特 勒恩
Original Assignee
瑞典商奥瑞克索股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2117005.5A external-priority patent/GB202117005D0/en
Priority claimed from GBGB2208144.2A external-priority patent/GB202208144D0/en
Priority claimed from GBGB2213306.0A external-priority patent/GB202213306D0/en
Application filed by 瑞典商奥瑞克索股份公司 filed Critical 瑞典商奥瑞克索股份公司
Publication of TW202329916A publication Critical patent/TW202329916A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0043—Non-destructive separation of the package, e.g. peeling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0061—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using pre-packed dosages having an insert inside
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/07—General characteristics of the apparatus having air pumping means
    • A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
    • A61M2205/073—Syringe, piston type

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Fire-Extinguishing By Fire Departments, And Fire-Extinguishing Equipment And Control Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW111145223A 2021-11-25 2022-11-25 包含生物醫藥藥物化合物之新穎醫藥組合物 TW202329916A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB2117005.5A GB202117005D0 (en) 2021-11-25 2021-11-25 New pharmaceutical composition
GB2117005.5 2021-11-25
GB2208144.2 2022-06-01
GBGB2208144.2A GB202208144D0 (en) 2022-06-01 2022-06-01 New pharmaceutical composition
GBGB2213306.0A GB202213306D0 (en) 2022-09-12 2022-09-12 New pharmaceutical composition
GB2213306.0 2022-09-12

Publications (1)

Publication Number Publication Date
TW202329916A true TW202329916A (zh) 2023-08-01

Family

ID=84367624

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111145223A TW202329916A (zh) 2021-11-25 2022-11-25 包含生物醫藥藥物化合物之新穎醫藥組合物

Country Status (11)

Country Link
US (1) US20240408212A1 (cg-RX-API-DMAC10.html)
EP (1) EP4436551A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024543125A (cg-RX-API-DMAC10.html)
KR (1) KR20240111761A (cg-RX-API-DMAC10.html)
AR (1) AR127783A1 (cg-RX-API-DMAC10.html)
AU (1) AU2022398370A1 (cg-RX-API-DMAC10.html)
CA (1) CA3239053A1 (cg-RX-API-DMAC10.html)
IL (1) IL313015A (cg-RX-API-DMAC10.html)
MX (1) MX2024006130A (cg-RX-API-DMAC10.html)
TW (1) TW202329916A (cg-RX-API-DMAC10.html)
WO (1) WO2023094818A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12414916B2 (en) 2021-06-10 2025-09-16 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
US12661315B2 (en) 2021-06-10 2026-06-23 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
CN118461230B (zh) * 2024-05-15 2026-07-10 中山大学 一种植物多糖纳米纤维膜及其制备方法和应用
US20260108465A1 (en) 2024-10-21 2026-04-23 Belhaven BioPharma Inc. Compositions, devices, and methods for intranasal delivery of dry powder epinephrine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19518810A1 (de) 1995-05-26 1996-11-28 Bayer Ag Nasal-Applikator
DE69913113T2 (de) 1998-03-10 2004-08-26 Valois S.A.S. Behälter, verfahren zur befüllung dieses behälter und abgabevorrichtung für das im behälter enthaltene pulver
FR2817847B1 (fr) 2000-12-08 2003-03-28 Tebro Dispositif de distribution de produit fluide ou pulverulent
LU90825B1 (en) 2001-09-06 2003-03-07 Iee Sarl Method for the determination of one or more parameters of a seat passenger
CA2540204A1 (en) 2003-10-09 2005-04-21 Bioactis Limited Device to deliver powdery medicine into nasal cavity
EP1834651A1 (en) * 2006-03-15 2007-09-19 Universiteit Gent Compositions and methods for veterinary vaccination
SG2013054218A (en) * 2008-01-15 2014-10-30 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
EP2266563A1 (en) 2009-06-11 2010-12-29 Charité-Universitätsmedizin Berlin (Charité) Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
US8827946B2 (en) 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
JP5623355B2 (ja) 2010-07-30 2014-11-12 オートリブ ディベロップメント エービー カーテンエアバッグ
CN104470569B (zh) 2012-06-28 2018-04-27 美国政府(由卫生和人类服务部的部长所代表) 用于疫苗和其它治疗试剂的鼻干粉递送系统
FR3007992B1 (fr) 2013-07-05 2018-01-26 Aptar France Sas Dispositif de distribution de produit fluide ou pulverulent.
JP6611720B2 (ja) * 2013-09-03 2019-11-27 ジョージア テック リサーチ コーポレイション 熱安定性ワクチン製剤及びマイクロニードル
CN104489669A (zh) * 2014-12-12 2015-04-08 深圳先进技术研究院 一种植物酵素益生菌粉及其制备方法
CN110996912A (zh) 2017-08-20 2020-04-10 福摩莱克斯医药创新有限公司 用于鼻内递送的干粉组合物
EP3698773A1 (en) * 2019-02-21 2020-08-26 Università degli Studi di Parma Composition and manufacturing of powders containing nanoadjuvants for mucosal vaccination
US10653690B1 (en) * 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
FR3098420B1 (fr) 2019-07-10 2021-07-09 Aptar France Sas Dispositif de distribution nasale de poudre
CN121265577A (zh) * 2020-05-18 2026-01-06 奥瑞克索股份公司 用于药物递送的药物组合物
FR3121047B1 (fr) 2021-03-29 2023-07-14 Aptar France Sas Dispositif de distribution nasale de poudre

Also Published As

Publication number Publication date
AR127783A1 (es) 2024-02-28
US20240408212A1 (en) 2024-12-12
AU2022398370A1 (en) 2024-05-30
EP4436551A1 (en) 2024-10-02
JP2024543125A (ja) 2024-11-19
MX2024006130A (es) 2024-06-04
KR20240111761A (ko) 2024-07-17
CA3239053A1 (en) 2023-06-01
IL313015A (en) 2024-07-01
WO2023094818A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
US20240408212A1 (en) Pharmaceutical composition comprising biopharmaceutical drug compounds
US7842310B2 (en) Pharmaceutical compositions in particulate form
CN104302278B (zh) 在回肠和阑尾上有活性的胃肠位点特异性口服接种疫苗制剂
US11364293B2 (en) Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens
JP2004532277A (ja) 噴霧凍結乾燥組成物
US20040213745A1 (en) Powder formulations of rSEB for improved vaccination
JP2024543125A5 (cg-RX-API-DMAC10.html)
US20260014251A1 (en) Compositions, methods, and uses for polynucleotide formulations for drying and prolonged storage
Zhen et al. Drying technologies for messenger RNA and other nucleic acid-lipid nanoparticles: advances in freeze-drying and beyond
CN118973556A (zh) 包含生物制药药物化合物的药物组合物
US20050002969A1 (en) Binary composition for prime-boost release of active ingredients like vaccines
CN118555964A (zh) 癌症治疗组合物及其用途
US20220409539A1 (en) Particles for multi-dose delivery
Gupta et al. Virus-like particles: Bridging immunization and precision drug delivery
US20260000621A1 (en) Compositions and methods of use for stabilizing and delivery of atomic layer deposition coating of agent-containing lipid-emulsion formulations
WO2026006624A1 (en) Stabilized and atomic layer deposition (ald)-coated lipid assembly-free polynucleotide-containing microparticles and uses thereof
CN118613491A (zh) Sars-cov-2 rna疫苗组合物及使用方法
De Villiers et al. Developments in drug delivery technologies: Molecular and crystal design, cellular response and targeted and site-specific delivery
WO2004052341A1 (en) Adjuvant compositions containing a sugar in crystalline form and aminoalkyl glucosaminide-4-phosphate